BioPharma Resources

Drugs by condition

Drugs approved for acid reflux (gerd)

Brand-name prescription drugs and biologics whose FDA label lists acid reflux (gerd) as an approved use. Matched on the label phrases: "gastroesophageal reflux disease".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

9

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

3

New molecular entities and new biologics

In development

2

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for acid reflux (gerd).

All approved drugs for acid reflux (gerd), by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 121 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Proton Pump Inhibitor (3)

  • Prevacid Lansoprazole · Takeda Pharms USA · 1995
  • Dexilant Dexlansoprazole · Takeda Pharms USA · 2009
  • Prevacid Lansoprazole · Takeda Pharms USA · 2002

Class not listed in FDA's data (6)

Drugs in development for acid reflux (gerd)

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • JP-1366Phase 34 trials

    Onconic Therapeutics Inc. · H. Pylori Eradication Therapy, Non-erosive Gastroesophageal Reflux Disease, Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)

  • DW4421Phase 31 trial

    Daewon Pharmaceutical Co., Ltd. · Erosive Reflux Disease, GERD (Gastroesophageal Reflux Disease)

5 discontinued brand-name drugs whose label still names it

More on acid reflux (gerd): recruiting trials · published research

Related in gastroenterology and liver: MASH (fatty liver disease) · Primary biliary cholangitis · Irritable bowel syndrome · Chronic constipation · Nausea and vomiting · Eosinophilic esophagitis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.